Undifferentiated Ovarian Carcinoma Recruiting Phase 2 Trials for Doxorubicin (DB00997)

IndicationStatusPhase
DBCOND0028876 (Undifferentiated Ovarian Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02364713MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal CancerTreatment